Antigen identification for Chlamydia vaccine development
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Chlamydia trachomatis is the most prevalent sexually transmitted infection (STI) in the US, with 1.64 million cases reported to the US Centers for Disease Control and prevention (CDC) in 2022. Women with untreated Chlamydia infection can develop pelvic inflammatory disease (PID) and suffer long-term reproductive harm including chronic pelvic pain, ectopic pregnancy, or infertility. There are no licensed vaccines for Chlamydia and a very limited vaccine pipeline. This application builds on our recent work demonstrating that Chlamydia- specific circulating memory and non-circulating TRM CD4 T cells can each provide protective immunity to the female reproductive tract. We will use new screening approach to, (i) identify target antigens recognized by both of these protective Chlamydia-specific memory CD4 T cells and validate these antigens, (ii) examine whether an mRNA vaccine approach can provide protection in the mouse model. Successful completion of these studies will provide a new foundation for vaccine development against a neglected disease that adversely affects the reproductive health of many young women in the US.
Grant Summary
Antigen identification for Chlamydia vaccine development is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $405K for university, nonprofit, healthcare org. Applications are due 2028-01-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $405K
2028-01-31
- 1Confirm your organization is eligible for Antigen identification for Chlamydia vaccine development from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Antigen identification for Chlamydia vaccine development: Frequently Asked Questions
Who is eligible for the Antigen identification for Chlamydia vaccine development?
Antigen identification for Chlamydia vaccine development is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Antigen identification for Chlamydia vaccine development provide?
Antigen identification for Chlamydia vaccine development provides up to $405K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Antigen identification for Chlamydia vaccine development deadline?
Applications for Antigen identification for Chlamydia vaccine development are due 2028-01-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Antigen identification for Chlamydia vaccine development?
To apply for Antigen identification for Chlamydia vaccine development, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.